Niko von Huetz Joins Saints Capital

Niko von Huetz has joined direct secondaries firm Saints Capital as director of European investments. He previously was a partner and investment director with Add Partners.


Saints Capital, a leading secondary direct investment firm, today announced that Niko von Huetz has joined the firm as Director of European investments. Mr. von Huetz previously worked as Investment Director and Partner at Add Partners, a pan-European, London-based ICT focused venture firm. Previously, Mr. Huetz worked with ICG & Partners and was Co-founder, VP Marketing & Business Development for Kokua Communications. He began his career as a Manager at leading strategy consultants, Booz.Allen & Hamilton.

“Niko’s venture and investment experience in Europe, coupled with his knowledge in the software, communications and internet services sector, make him a great addition to our team,” said Ken Sawyer, Managing Director at Saints Capital.

Saints acquires direct secondary assets from distressed sellers, and currently has 27% of its assets invested in Europe. With the opening of a London office last year and a team of investment professionals in the UK, Saints is poised to take advantage of the growing market opportunity in Europe. In 2008, Saints acquired interests in ten companies from Innovacom, an active early stage investor based in Paris.

Saints Capital has also promoted two investment professionals. Zack Scott, MD, was promoted to Vice President and Mike Boggs was promoted to Senior Associate. Both investment professionals have evaluated a number of secondary portfolio investment opportunities in the healthcare space. Dr. Scott sits on the boards of VisionCare and Cianna Medical, and is a board observer at Spiration. He joined Saints from Burrill & Company where he made investments in healthcare services, diagnostics and pharmaceuticals. Previously, Dr. Scott was a General Surgery resident at Oregon Health Science University. While at Saints, Mr. Boggs helped complete the secondary portfolio acquisition of medical device assets from Boston Scientific and growth equity companies from Safeguard Scientifics. He is a board observer at Laureate Pharma and Navix Diagnostics. Mr. Boggs joined Saints in 2007 from RBC Capital Markets where he was an Investment Banking Analyst in the Healthcare Group. His experience includes transactions in equity, convertible debt and M&A activity.

About Saints Capital

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit